CoChat

The Lifetime Medical Cost Savings From Preventing HIV in the United States

Open access

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Enhanced HIV prevention interventions, such as preexposure prophylaxis for high-risk individuals, require substantial investments. We sought to estimate the medical cost saved by averting 1 HIV infection in the United States. METHODS: We estimated lifetime medical costs in persons with and without HIV to determine the cost saved by preventing 1 HIV infection. We used a computer simulation model of HIV disease and treatment (CEPAC) to project CD4 cell count, antiretroviral treatment status, and mortality after HIV infection. Annual medical cost estimates for HIV-infected persons, adjusted for age, sex, race/ethnicity, and transmission risk group, were from the HIV Research Network (range, $1854-$4545/mo) and for HIV-uninfected persons were from the Medical Expenditure Panel Survey (range, $73-$628/mo). Results are reported as lifetime medical costs from the US health system perspective discounted at 3% (2012 USD). RESULTS: The estimated discounted lifetime cost for persons who become HIV infected at age 35 is $326,500 (60% for antiretroviral medications, 15% for other medications, 25% nondrug costs). For individuals who remain uninfected but at high risk for infection, the discounted lifetime cost estimate is $96,700. The medical cost saved by avoiding 1 HIV infection is $229,800. The cost saved would reach $338,400 if all HIV-infected individuals presented early and remained in care. Cost savings are higher taking into account secondary infections avoided and lower if HIV infections are temporarily delayed rather than permanently avoided. CONCLUSIONS: The economic value of HIV prevention in the United States is substantial given the high cost of HIV disease treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mlr.0000000000000308

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 4

  1. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014 clinical practice guideline. Center for Disease Control and Prevention; [Accessed May 6, 2014]. Available at: <http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf>. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Preexposure%20prophylaxis%20for%20the%20prevention%20of%20HIV%20infection%20in%20the%20United%20States%20-%202014%20clinical%20practice%20guideline&)]
  2. Cost-effectiveness of preventing AIDS complications. Massachusetts General Hospital; [Accessed December 18, 2013]. Available at: <http://web2.research.partners.org/cepac/mainpage.html>. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Cost-effectiveness%20of%20preventing%20AIDS%20complications&)]
  3. Red Book. Montvale, NJ: Thompson PDR; 2009. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=Red%20Book&publication_year=2009&)]
  4. Althoff KN. Personal communication to K. Gebo requesting NA-ACCORD data for CD4 count at presentation to care stratified by race, sex, and risk group (2007 data) 2012 [[Google Scholar](https://scholar.google.com/scholar_lookup?Althoff%20KN.%20Personal%20communication%20to%20K.%20Gebo%20requesting%20NA-ACCORD%20data%20for%20CD4%20count%20at%20presentation%20to%20care%20stratified%20by%20race,%20sex,%20and%20risk%20group%20(2007%20data)%202012)]

Cited by

See all 136

Metadata

Authors
Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E.
Affiliations
  • Brigham and Women's Hospital (US)
  • Agency for Healthcare Research and Quality (US)
  • Massachusetts General Hospital (US)
  • Johns Hopkins University (US)
Corresponding author
  • Schackman, Bruce R.
  • Walensky, Rochelle P.
Venue
Medical Care
Published
2015-04
Volume
53
Issue
4
Pages
293-301
ISSN
0025-7079 (ISSN-L)
OpenAlex
W2049404409
Cited by
123
References
44
Citations by year
2026: 9 · 2025: 9 · 2024: 7 · 2023: 8 · 2022: 9 · 2021: 11 · 2020: 14 · 2019: 19 · 2018: 12 · 2017: 10 · 2016: 8 · 2015: 6
FWCI
9.34
Type
journal article
Language
en
Open access
Locations
  • Medical Care (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Public Health Service (HHSA 290-2011-00007C, HHSH250201200008C)
  • National Institute of Mental Health (R25MH094612)
  • National Institute of Allergy and Infectious Diseases (R37 AI42006, R37AI042006, P30AI094189)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
HIV prevention, lifetime medical costs, cost reduction, pre-exposure prophylaxis, antiretroviral therapy, HIV disease progression, CD4 count, HIV mortality, secondary infection
MeSH terms
Adolescent, Adult, Computer Simulation, Humans, Middle Aged, United States, HIV Infections, Cost Savings, Health Care Costs, CD4 Lymphocyte Count, Models, Economic, Anti-Retroviral Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Lifetime Medical Cost Savings From Preventing HIV in the United States. https://app.cochat.ai/papers/10.1097/mlr.0000000000000308
The paper
Schackman, B. R., Fleishman, J. A., Su, A. E., Berkowitz, B. K., Moore, R. D., Walensky, R. P., Becker, J. E., Voss, C., Paltiel, A. D., Weinstein, M. C., Freedberg, K. A., Gebo, K. A., & Losina, E. (2015). The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care. https://doi.org/10.1097/mlr.0000000000000308

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.